Most Clicked StoriesMore >


Lilly-Boehringer's biosimilar insulin gets tentative approval from FDA

BIO SmartBrief | Aug 19, 2014

Eli Lilly and Co. and Boehringer Ingelheim received tentative approval from the FDA for Basaglar, their biosimilar version of Sanofi's diabetes treatment Lantus. The agency approved the use of the biosimilar insulin for adult type 2 diabetes patients and for use along with insulin at mealtimes for type 1 diabetes patients. PharmaTimes (U.K.) (08/18)


Pfizer partners with 23andMe to study genetic links to IBD

BIO SmartBrief | Aug 13, 2014

Roche offers $10B to take full control of Chugai, sources say

BIO SmartBrief | Aug 18, 2014

BIO, others criticize FDA's draft biosimilarity guidelines

BIO SmartBrief | Aug 18, 2014

Several major drugmakers reportedly interested in buying InterMune

BIO SmartBrief | Aug 14, 2014

Drugmakers ramp up efforts to develop cure for Ebola virus

BIO SmartBrief | Aug 13, 2014

Merck's insomnia drug Belsomra wins FDA approval

BIO SmartBrief | Aug 14, 2014

NewLink's Ebola vaccine may soon enter human trials

BIO SmartBrief | Aug 14, 2014

Allergan nabs TARIS' bladder pain drug in deal worth as much as $587.5M

BIO SmartBrief | Aug 15, 2014

Biogen's MS drug gains FDA clearance

BIO SmartBrief | Aug 18, 2014


Find BIO SmartBrief Issues by Date:



BIO News More >


Present your industrial biotech research in San Diego

BIO SmartBrief | Aug 19, 2014

Registration is open for the BIO Investor Forum!

BIO SmartBrief | Aug 18, 2014

Announcing the BIO Latin America Conference!

BIO SmartBrief | Aug 15, 2014

New BIO Survey Tool: FDA/Sponsor Interactions During Drug Development

BIO SmartBrief | Aug 14, 2014

Faster & better connections with quality R&D vendors

BIO SmartBrief | Aug 12, 2014




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more